For starters, it could cause harm. All vaccines carry the risk of injury or death. During trials, nine individuals developed arthritis after receiving the vaccine versus three for the placebo, out of approximately 21,000 individuals in that trial. Nine kids with arthritis after receiving the vaccine might not seem like a big deal in the grand scheme of things. After all, arthritis is better than cancer, right? That depends. Given the fact that cervical cancer is relatively rare, highly preventable and most often successfully treated early on, maybe the risk of arthritis — a painful and often debilitating disease — isn’t a worthwhile trade-off.

In order to learn the truth about an unknown, honest science dictates that we have to compare it to a known. When most people think about a vaccine placebo, they are probably thinking about saline. But that’s not what was used during trials. The “placebo” in this case was an aluminium-containing shot. The vaccine itself also contains aluminium. Aluminium hydroxide is what’s known as an adjuvant — it stimulates immune response. Studies in both animals and humans have found that aluminium adjuvants can cause death of brain cells. Similar studies have also shown that aluminium adjuvants in vaccines can cross the blood-brain barrier, as well as cause injection-site inflammation leading to chronic joint and muscle pain and fatigue. Aluminium adjuvants have never been subjected to clinical trials for safety. Read that again: Although the metal has been used in vaccines for decades, it has never been rigorously studied for long-term safety. So perhaps the 1 case of lupus and 2 cases of arthritis out of 9,701 participants who received the “placebo” were not just statistical anomalies. Maybe it was the aluminium. Perhaps that would also explain the 1 case of juvenile arthritis, 2 cases of rheumatoid arthritis, 5 cases of arthritis and 1 case of reactive arthritis in 11,813 Gardasil recipients. We’ll never know. (Some of the trial participants did, in fact, receive straight saline but there’s no way to tell from the data released which cases are which.) More importantly, a reactive placebo artificially decreases the appearance of danger of an experimental vaccine in a clinical trial because the drug company only has to prove that adverse events weren’t statistically significant in the vaccine group versus the placebo group. So using aluminium-containing placebos falsely inflates the adverse-event data of the “placebo” group, making the vaccine look relatively safe by comparison. Gardasil contains 225 mcg of aluminium. Neither Merck nor the U.S. FDA would answer my questions as to how much aluminium was used in the placebo. (Sanofi Pasteur MSD is marketing the vaccine in Europe and is a joint venture of French company Sanofi Pasteur and U.S. pharmaceutical company Merck.) Clinical trial investigators dismissed most of the 102 serious adverse events including 17 deaths that occurred in the clinical trials as unrelated to the study. But given the reactivity profile of aluminium, can we really say that for sure?

Those who received the vaccine reported even more serious adverse events such as gastroenteritis, appendicitis, pelvic inflammatory disease, asthma, bronchospasm and arthritis. In a never before done study, scientists recently found a link between aluminium in vaccines and symptoms associated with Parkinson’s, amyotrophic lateral sclerosis (ALS, or Lou Gehrig’s disease) and Alzheimer’s. “This is suspicious,” neuroscientist Chris Shaw told the Georgia Straight, Canada’s largest urban weekly. “Either this [link] is known by industry and it was never made public, or industry was never made to do these studies by Health Canada. I’m not sure which is scarier.” Shaw said there could be 10,000 studies showing aluminium hydroxide is safe to be injected, but that he hasn’t been able to find one study that looked beyond the first few weeks of injection. The reason this is significant, according to Shaw, is that neurological damage can take years to manifest.

Females in the United States number 140 million people, comprising over half of the total population

ancer screening. An estimated 662,870 women will be diagnosed with cancer in 2005, and cancer is projected to lead to death for 275,000 women. An estimated 211,240 women will be diagnosed with breast cancer and 10,370 with cervical cancer; 40,410 and 3,710 women are projected to die of breast and cervical cancer, respectively.4 Mammograms and Pap tests are an effective means of reducing the incidence of late stage breast and cervical cancers, respectively, and mortality caused by these cancers.

Treatment of heart attack. Each year, about half a million women die of heart disease5; it is the leading cause of death for both women and men.

A Pap test is done to look for changes in the cells of the cervix . During a Pap test, a small sample of cells from the surface of the cervix is collected by your health professional. The sample is then spread on a slide (Pap smear) or mixed in a liquid fixative (liquid-based cytology) and sent to a lab for examination under a microscope. The cells are examined for abnormalities that may indicate abnormal cell changes, such as dysplasia or cervical cancer.It is important to have your first Pap test within 3 years of having sex for the first time or by age 21. You may be able to stop having regular Pap tests after you are 65 to 70 years of age, if you have had 3 normal Pap tests in a row, you do not have a high risk of cervical cancer, and you have not had any new sex partners over the last 3 years. If you do not have a uterus, you don’t need a Pap test as long as cervical dysplasia or cervical cancer was not the reason your uterus was removed. You may need more frequent Pap tests if you have had an abnormal Pap test in the past. Talk with your health professional about how often you should have Pap tests.A high-risk type of the human papillomavirus (HPV) is the cause of most cases of cervical cancer. In women older than 30, an HPV test may be done at the same time as a Pap test. A vaccine (Gardasil) is available to prevent infection with the types of HPV that are most likely to cause cervical cancer.

How long does vaccine protection last? Will a booster shot be needed? The length of vaccine protection (immunity) is usually not known when a vaccine is first introduced. So far, studies have found that vaccinated persons are protected for five years. More research is being done to find out how long protection will last, and if a booster dose of vaccine will be needed.

There are no federal laws requiring the immunization of children.

How much will the HPV vaccine cost? The retail price of the vaccine is $120 per dose ($360 for full series).

"Also, the public needs to know that with vaccinated women and women who still get Pap smears (which test for abnormal cells that can lead to cancer), some of them will still get cervical cancer."The reason, she said, is because the vaccine does not protect against all HPV viruses that cause cancer - it's only effective against two that cause about 70 percent of cervical cancers.For months, Harper said, she's been trying to convince major television and print media to listen to her and tell the facts about the usefulness and effectiveness of this vaccine.

Methods 277 young women (mean age 20·2 years [SD 1·7]) were randomly assigned to quadrivalent HPV (20 É g type 6, 40 É g type 11, 40 É g type 16, and 20 É g type 18) L1 virus-like-particle (VLP) vaccine and 275 (mean age 20·0 years [1·7]) to one of two placebo preparations at day 1, month 2, and month 6. For 36 months, participants underwent regular gynaecological examinations, cervicovaginal sampling for HPV DNA, testing for serum antibodies to HPV, and Pap testing. The primary endpoint was the combined incidence of infection with HPV 6, 11, 16, or 18, or cervical or external genital disease (ie, persistent HPV infection, HPV detection at the last recorded visit, cervical intraepithelial neoplasia, cervical cancer, or external genital lesions caused by the HPV types in the vaccine). Main analyses were done per protocol. Findings Combined incidence of persistent infection or disease with HPV 6, 11, 16, or 18 fell by 90% (95% CI 71-97, p<0·0001) in those assigned vaccine compared with those assigned placebo. Interpretation A vaccine targeting HPV types 6, 11, 16, 18 could substantially reduce the acquisition of infection and clinical disease caused by common HPV types. AUTHOR DISCUSSION We have shown that a multivalent vaccine is efficacious against HPV types that cause cancer and genital warts. Over 35 months’ follow-up, incidence of persistent infection associated with HPV 6, 11, 16, or 18 decreased by 89% in women allocated active vaccine who had at least one dose (ie, the modified intention-to-treat population) compared with those allocated placebo. Vaccine efficacy was 90% in the per-protocol efficacy population, suggesting that the vaccine was protective even during the vaccination period. For example, during the course of vaccination (day 1 through month 7), three women assigned active vaccine and five women assigned placebo were detected with HPV 18 DNA. Of these, only one was verifiable persistent infection (in the placebo group). Thus, one woman allocated placebo and no women allocated active vaccine developed persistent HPV 18 infection during the vaccination period. Furthermore, efficacy with regard to clinical disease associated with HPV 6, 11, 16, or 18 was 100%.

Methods Study design A phase II randomised, multicentre, double-blind placebo-controlled study of a quadrivalent HPV (type 6, 11, 16, and 18) L1 VLP vaccine was done in two parts. Part A was a sequential dose-escalation safety assessment, in which participants, investigators, and staff were blinded as to assignment of vaccine or placebo, but not to assignment of doses in the active-treatment group. Part B was a fully blinded dose-ranging assessment of immunogenicity and efficacy. Study procedures for individuals in part A and part B were identical. The results presented in this article are from part B. 1158 women aged 16-23 years were recruited in Brazil, Europe, and the USA. The study enrolled healthy women, who were not pregnant, had no previous abnormal Pap smears, and reported a lifetime history of four or fewer male sex partners. Enrolment of virgins was restricted to women who were 18 years or older and who were seeking contraception. This study did not exclude women with previous HPV infection. Participants were required to use effective contraception during the trial. The active quadrivalent vaccine was a mixture of four recombinant HPV type-specific VLPs (Merck Research Laboratories, West Point, PA, USA) consisting of the L1 major capsid proteins of HPV 6, 11, 16, and 18 synthesised in Saccharomyces cerevisiae.10,14,16 The four VLP types were purified and adsorbed onto amorphous aluminium hydroxyphosphate sulfate adjuvant. The placebo consisted of the same adjuvant and was visually indistinguishable from vaccine. Three preparations of a quadrivalent HPV types 6, 11, 16, and 18 L1 VLP were used. The three preparations were : 20 É g type 6, 40 É g type 11, 40 É g type 16, and 20 É g type 18, with 225 É g aluminium adjuvant ; 40 É g type 6, 40 É g type 11, 40 É g type 16, and 40 É g type 18, with 225 É g aluminium adjuvant ; and 80 É g type 6, 80 É g type 11, 40 É g type 16, and 80 É g type 18, with 395 É g aluminium adjuvant. The study had two placebo groups with adjuvant doses of 225 É g or 450 É g for appropriate safety comparisons. 0·5 mL vaccine or placebo was given by intramuscular injection at day 1, month 2, and month 6. After vaccination, participants were observed for 30 min. Temperatures were also recorded orally every day in the evening for 5 days after vaccination, and the participant noted adverse events by standard diary card for 14 days after vaccination. Gynaecological examination was done at day 1 and at months 7, 12, 24, and 36. A ThinPrep™ Pap test (Cytyc, Boxborough, MA, USA) and external genital, lateral vaginal, and cervical swabs for PCR analysis of HPV were obtained from all participants at day 1 and at months 7, 12, 18, 24, 30, and 36. Biopsy samples of external genital lesions identified during the study were taken, and serum samples were obtained at day 1 and months 2, 3, 6, 7, 12, 18, 24, 30, and 36. This study was done in accordance with national or local requirements for ethics-committee review, informed consent, and other statutes or regulations regarding the protection of the rights and welfare of those participating in biomedical research. All individuals, or their parents or legal guardians, gave written informed consent after review of the protocol procedures. The aim of the study was to assess a quadrivalent HPV L1 VLP vaccine in terms of the composite primary endpoint of persistent infection associated with HPV 6, 11, 16, or 18, or cervical or external genital disease compared with placebo. Women with persistent infection were defined as those who had the same vaccine-HPV-type DNA in cervicovaginal samples obtained 7 months after vaccination as those obtained from two or more consecutive visits (required to be 4 months or longer apart unless at least one tissue sample was diagnosed as cervical disease by a panel of pathologists), or as those who had vaccine-HPV-type DNA detected in a sample recorded during the last visit before being lost to follow-up. HPV-associated disease was defined as a tissue sample diagnosed as CIN by a panel of pathologists 7 months after vaccination ; vulval intraepithelial neoplasia ; vaginal intraepithelial neoplasia ; external genital warts ; or cervical, vulval, or vaginal cancer with vaccine-HPV-type DNA detected in tissue from, or in a swab of, the same lesion and in cervicovaginal samples obtained at the visit before the biopsy visit.

AHRP's stated rationale for objecting to a policy mandating Merck's HPV vaccine in 11 year old girls [Link] is validated by an internationally recognized expert in the field who tested the vaccine in clinical trials.Dr. Diane M. Harper, a lead researcher in the development of the human papilloma virus vaccine, who says giving the drug to 11-year-old girls "is a great big public health experiment." Dr. Harper, a scientist, physician, professor and the director of the Gynecologic Cancer Prevention Research Group at the Norris Cotton Cancer Center at Dartmouth Medical School in New Hampshire, said: "It is silly to mandate vaccination of 11- to 12-year-old girls There also is not enough evidence gathered on side effects to know that safety is not an issue." All of her trials have been with subjects ages 15 to 25. "This vaccine has not been tested in little girls for efficacy. At 11, these girls don't get cervical cancer - they won't know for 25 years if they will get cervical cancer."

She believes the ideal way of administering the new vaccine is to offer it to women ages 18 and up. At the time of their first inoculation, they should be tested for the presence of HPV in their system. If the test comes back negative, then schedule the follow-up series of the three-part shots.

But if it comes back positive? "Then we don't know squat, because medically we don't know how to respond to that," Harper said.

WASHINGTON, DC, October 5, 2007 (LifeSiteNews.com) - Judicial Watch, the public interest group that investigates and prosecutes government corruption, yesterday released new documents obtained from the U.S. Food and Drug Administration (FDA) under the provisions of the Freedom of Information Act, detailing a total of as many as eleven deaths related to Merck's HPV vaccine Gardasil.  Those deaths resulted between June 8, 2006 - when the vaccine received approval from the U.S. Food and Drug Administration (FDA) - and August 2007 when the latest data was available. The adverse reports coming from the HPV vaccine are increasing daily at an alarming rate.  A LifeSiteNews.com report which scanned a publicly available database of adverse affects coming from the HPV vaccine found 3,137 adverse effects reported on September 28, 2007.  Today the US Government's Vaccine Adverse Event Reporting System (VAERS) lists 3,779 adverse effects.  52 of the cases were deemed "life threatening" and 119 required hospitalization. In one case highlighted by Judicial Watch a 17 year old girl who was vaccinated in June 2007 died the very day she was vaccinated.  According to the report, she "was vaccinated with a first dose of Gardasil…During the evening of the same day, the patient was found unconscious (lifeless) by the mother. Resuscitation was performed by the emergency physician but was unsuccessful.  The patient subsequently died." Other serious reported side effects associated with Gardasil include paralysis, Bells Palsy, Guillain-Barre Syndrome, and seizures.  Says one report: "Initial and follow-up information has been received from a physician concerning an "otherwise healthy" 13 year old female who was vaccinated with her first and second doses of Gardasil.  Subsequently, the patient experienced…paralysis from the chest down, lesions of the optic nerve…At the time of the report, the patient had not recovered." "In light of this information, it is disturbing that state and local governments might mandate in any way this vaccine for young girls," said Judicial Watch President Tom Fitton.  "These adverse reaction reports suggest the vaccine not only causes serious side effects, but might even be fatal." The toll from the HPV vaccine may be greater still.  Judicial Watch filed its request on August 20, 2007, and received the adverse event reports from the FDA on September, 13 2007, in what the agency described as a "partial response." On October 3, 2007, Judicial Watch filed a new lawsuit against the FDA for its failure to fully respond to Judicial Watch's FOIA request as required by law.

Vienna, Virginia - The National Vaccine Information Center (NVIC), the nation's leading vaccine safety and informed consent advocacy organization, is urging state legislatures to investigate the safety and cost of mandating Merck's HPV vaccine (GARDASIL) for all pre-adolescent girls before introducing legislation amending state vaccine laws. In an analysis of reports made to the federal Vaccine Adverse Event Reporting System (VAERS) since the CDC's July 2006 universal use recommendation for all young girls, NVIC found reports of loss of consciousness, seizures, joint pain and Guillain-Barre Syndrome. In a separate evaluation of costs for young girls being vaccinated in private pediatrician offices, NVIC discovered that parents living in the Washington, D.C. area will be paying between $500 and $900 to have their daughters receive three doses of GARDASIL. "GARDASIL safety appears to have been studied in fewer than 2,000 girls aged 9 to 15 years and it is unclear how long they were followed up. [1] VAERS is now receiving reports of loss of consciousness, seizures, arthritis and other neurological problems in young girls who have received the shot," said NVIC President Barbara Loe Fisher. "At the same time, parents who take their daughters to private pediatricians are going to be shocked to find that they will be paying two to three times the widely publicized $360 cost for the three-dose series. The cost is going to break the pocketbooks of parents and break the banks of both insurance companies and taxpayers, when the reality is that almost all cases of HPV-associated cervical cancer can be prevented with annual pap screening of girls who are sexually active." Between July 2006 and January 2007, there have been 82 reports of adverse events filed with VAERS following receipt of GARDASIL by girls and boys ranging in age from 11 to 27 years. Reaction reports have come from 21 states, including Virginia and the District of Columbia. All but three of the reports were for adverse events which occurred within one week of vaccination and more than 60 percent occurred within 24 hours of vaccination. "The most frequent serious health events after GARDASIL shots are neurological symptoms," said NVIC Health Policy Analyst Vicky Debold, RN, Ph.D. "These young girls are experiencing severe headaches, dizziness, temporary loss of vision, slurred speech, fainting, involuntary contraction of limbs (seizures), muscle weakness, tingling and numbness in the hands and feet and joint pain. Some of the girls have lost consciousness during what appears to be seizures." Debold added "The manufacturer product insert should include mention of syncopal episodes, seizures and Guillain-Barre Syndrome so doctors and parents are aware these vaccine adverse responses have been associated with the vaccine."

HPV is the most common sexually transmitted infection in the U.S. and most persons naturally clear the infection from the body without symptoms. [3] However, many years of chronic HPV infection is associated with a higher risk of pre-cancerous changes in the cervix that can lead to cancer unless diagnosed and treated promptly. High risk factors for chronic HPV infection include smoking, long-term use of oral contraceptives and co-infection with HIV, herpes and chlamydia. [4] There has been a more than 70 percent drop in cervical cancer deaths in American women since the 1950's due to routine pap smears and nearly all cervical cancers can be prevented with regular pap smear screening and treatment. [5]

CDC backpedals on vaccination recommendations Healthcare workers oblivious to their participation in mass medical experimentation COEUR D'ALENE -- The Centers for Disease Control and Prevention (CDC) Immunization Update for Sept. 14, broadcast via satelite to public health institutions all over the nation, was an installment of the periodic program which served two specific functions: It served notice that influenza vaccine will be late and in short supply this year and it cleverly backpedaled on several aspects of previous CDC vaccination recommendations because too many people have died or become permanently damaged as a result. The CDC must have known it would have to play hardball with health professionals to overcome recent failings with regard to vaccination policy: Mercury-based preservative thimerosal has been banned from vaccines amid claims that it may be harmful and news that the oral polio has been responsible for spreading the disease rather than preventing it and contains the carcinogenic monkey virus SV-40. To compel audience participation and compliance, the CDC urged the health professionals in the audience to fill out the form to receive continuing education credit for watching the program and fill out the evaluation form and send them both in to the CDC. For their trouble, the CDC promised to mail them a collectible “Star Wars” pro-vaccination poster. The ruse apparently worked as the 25 women and one man in attendance accepted the explanations from program host CDC National Immunization Program Director Dr. William Atkinson for vaccination policies that may have been responsible for the injuries and deaths of thousands of people in over the last 30 years. Promise of a “collectible” poster from the 70s also helped these healthcare professionals to accept the new recommendations without questioning whether or not they might be lethal as well. Pneumococcus vaccine

Hepititis B There is a new, two-dose, thimerosal-free hep B vaccine manufactured by Merck and Smith/Kline. The CDC recommends that all infants be vaccinated against hep B before leaving the hospital. “Infants have been our emphasis over the last few years,” explained Atkinson. Hep B is primarily spread through intravenous drug use and promiscuous sex. For the CDC to recommend that all infants receive hep B vaccine must be because the federal agency expects babies to start sharing needles and engaging in promiscuous sex immediately upon leaving the hospital or the CDC believes it is safer, for the sake of the children, to assume that all mothers are intravenous drug abusers with multiple sex partners. The American Association of Pediatricians (AAP) recommended that hep B vaccine be delayed until six months of age due to thimerosal content. But, since thimersal has been removed, the AAP recommends that infants begin receiving the shots by no later than two months.

Polio vaccine “Today may be the last day we talk about polio vaccine,” Atkinson said. The CDC no longer recommends the administration of the oral polio vaccine (OPV) since it has been proven the vaccine causes outbreaks of the disease and contains the carcinogenic SV-40 monkey virus. Atkinson did mention OPV may be used in the event that parents refuse to have their child injected with the third and fourth doses of Inactivated Polio Vaccine, or if the child is traveling to a country where polio may be present within 4 weeks -- but that will be only until the end of this year as supplies of OPV will run out and they will not be replaced. Atkinson promised that in a few more years polio will be wiped out forever and will not be part of the recommended vaccination regimen. “The end of polio disease is in sight,” he said and added that China was just certified “polio free” this year. Historical references to 200 years of polio eradication efforts show that polio has never been controlled through vaccination. The definition of the disease just changes to become paralytic meningitis based upon the vaccination status of the individual.

What Your Doctor May Not Tell You about Children's Vaccinations By Stephanie Cave, Deborah Mitchell

He defines CFS as an epidemic illness, one which occurs primarily in the late summer and fall. It is typified by an acute onset of symptoms which vary from malaise to severe non-stop headaches and body pains now known in the US as fibromyalgia or myalgias. It is also accompanied by muscle weakness which develop alongside the pain symptoms and changes in brain function. The change in brain function is in several areas with one, a measurable decrease in the expected IQ, and, two, major cognitive losses that is, loss of sensory abilities to define one’s environment. which is very traumatic for the patients. Physicians have found very few physical modalities of the disease to help them to further diagnose the disease. The disease process, he adds, very much resembles poliomyelitis in its incubation period. Prior to 1962, before polio immunization became generalized. epidemics of CFS like disease occurred concurrently with polio epidemics. A lot of people at that time felt that there may be a type of poliomyelitis-type injury without the paralytic dysfunction. "My supposed expertise with hep B immunisation. And I say "supposed" because we know almost nothing….We know very little about hep B disease. We have no statistics in Canada, serious statistics. We don’t know, for instance, how many children in Canada die of it every year. There are no statistics. We don’t know who the people who fall ill with hep B are. Are they Haitian immigrants? Are they people who have just arrived from China? There are no government statistics on this information…. Why are we, in a time of major economic, medical and financial difficulty, spending literally a billion dollars, because that is what it would cost to immunise everybody in Canada against hepatitis B, for something in which we have the lowest risk in the world, for which we have no statistics, and for which there is no serious investigation on the side effects? I would not for a minute say not to take hep B immunisation if you work in a hospital dealing with blood products….We have to know what we are doing in medicine before we go and immunise tens of thousands, hundreds of thousands of children…Because if they develop brain dysfunction after hep B immunisation when they’re in kindergarten, who in the world will know the reason if they fail grades one, two, three and four? Was it because they were stupid, not motivated, not intellectually able, or on drugs? Who is going to know if it is that or if they were brain dysfunctions due to immunisations that, we know, occur to minor degrees in many types of immunisations? I did have a chance to spend a couple of evenings with the man in charge of getting the American soldiers ready for the Gulf (in Baton Rouge). He was in charge of anti-chemical, anti-germ warfare. He told me that many of the Gulf War Syndrom people were hospitalised immediately after massive immunisations and never got to the Gulf. I have never seen that written up. It is very interesting to note that hep B immunisation was only given to those people sent to the Gulf who were mediacl personnel, because they did not feel there was a risk for the regular soldier. Now, if the American government did not feel it was a risk to people in combat, it makes us wonder why we are giving it to our children today. We looked at hep B immunisation in Quebec province because one nurse phoned us saying she had CFS after having hep B immunization.....About a month later the same nurse called again, she now had 5 other nurses in the area who had fallen ill with CFS-like symptoms after the vaccine, all were unable to return to work. I told her to phone the maker, Merck. She told me she did and they said the 6 nurses were the only persons in the whole world that had ever had a serious side effect and therefore there couldn't possibly be a link. And, they told her that she was the only person who had ever phoned....she said that when her doctor phoned, he too was told he was the only person in the world that had ever called, and when each of the doctors of the other nurses called in, each was told the same thing. I also called Merck...and they said.."Oh Dr Hyde, you are the only doctor in all of Canada that has ever contacted us with such a complaint."

This same nurse....(had) amassed 20 or 30 names of individuals, all post hep B immunisation cases...We received close to 120 calls from nurses and health care workers in the Quebec area with problems...many were severely disabled." Dr Hyde. Dr Hyde mentioned that the investigation into the hep B vaccine raised after his efforts was funded, organised and run by a pharmaceutical company. He was not invited. "Nor was Dr. Phaneuf who has over 100 cases of post-hepatitis B immunisation in Quebec…Nobody who had ever published a paper on post-hepatitis immunisation adverse reaction was invited (to the Toronto conference on hepatitis B). So it was a very one sided meeting." All paid for by Merck. When he asked the government for a copy of the research they said they had completed using the list of hepatitis B "victims" he had provided, he was told that it had been destroyed for lack of space! Reproduced with permission of Here’s The Key Inc, CP309, Waterloo, Qc JOE 2NO, Canada. Tel: 001 450 297 2533. Fax: 001 450 297 4140 Selected extracts taken from The Trial of the Medical Mafia by Jochim Schafer ISBN 2921783029. Available from: Whale Books, UK. Tel: 01981 240 125. To reach Guylaine Lanctot, M.D. Tel: 001 514 297 4128. Fax: 001 514 297 4140 [Vaccination]  [CFS/ME & vaccines]  [Dr Lanctot]

Shots In The Dark by Barbara Loe Fisher   The worldwide acceptance of mass vaccination to suppress infectious childhood diseases once fiercely resisted is one of the most successful public relations stories in the history of medicine. As a result, epidemics of smallpox, which once swept through 18th- and 19th-century port cities such as Halifax, New York, and Boston without warning and cut down entire families, are now dry facts relegated to medical books. Images of children struggling through whooping cough, walking down the street coughing spasmodically, and stopping at curbs to spit up sticky mucus are only fading memories for grandparents alive to talk about what their parents told them.  Baby boomers and their parents still remember lining up in school in 1955 for polio vaccinations, with the hope that this magic bullet would keep them out of the dreaded iron lung.  Mass vaccination has dramatically suppressed childhood diseases. In Canada, recorded diphtheria cases dropped from 9,000 in 1924 to two to five by 1994.  When measles vaccination began in the United States between 1963 and 1965, doctors reported more than 400,000 cases annually; by 1995, that number had dwindled to 309. Cases of tetanus are almost unheard of in North America and Europe.   Yet the universal use of vaccines as a worthy goal that prevents needless suffering and that benefits all mankind has begun to be challenged.   The voices of critics are heard in the living rooms of families whose children have been injured or have died from reactions to routine childhood vaccinations, and in courtrooms, where parents are suing vaccine makers and challenging mandatory vaccination laws. In the U.S. Congress, legislators who have heard them have set up a vaccine injury compensation program. At scientific conferences and in the pages of prestigious medical journals, researchers and physicians are risking their careers by discussing vaccine side effects.

Today, vaccinations are big business. In 1995, an international high-technology research firm, Frost & Sullivan, projected that the worldwide human vaccine market will increase from $2.9 billion to more than $7 billion by the year 2001.   Public health officials in every country assist the industry�s growth, often by force of laws that ensure citizens use about a dozen different viral and bacterial vaccines, including ones to suppress even generally mild childhood diseases such as chicken pox. Traditional public health measures, improving sanitation, nutrition, living conditions, health education, and access to affordable medical care, especially in underprivileged populations often take a backseat to achieving a 100 per cent vaccination rate.   Most medical doctors consider vaccines their single most important tool in protecting public health. Few would question the profound importance of vaccines to public health, wrote Richard B. Johnston, Jr., MD, medical director of the March of Dimes and chairman of the Institute of Medicine Vaccine Safety Committee, in a 1994 National Academy of Sciences report, 

Adverse Events Associated with Vaccines Not only have deaths from the most common childhood infections been almost eliminated, but also so have the devastating morbidities of diseases like measles, paralytic polio, and congenital rubella. This revolution has . . . led to major savings in medical costs and gains in work productivity, as well as to reductions in deaths and suffering.   An ancient philosophical dispute goes modern   The whole idea of man versus nature can be traced back to the origins of western medicine more than 2,000 years ago. In a four-volume book series Divided Legacy: A History of Schism in Medical Thought by medical historian Harris L. Coulter, PhD, the centuries-old war between empiricism and rationalism in medicine is revealed as a contest between two competing health philosophies. Is each individual governed by a vital force that, through unique reactions to external stimuli, is capable of participating in the healing process, as empiricists, including Hippocrates, have maintained?  Or are all human organisms simply a series of complex chemical reactions governed by the laws of physics, chemistry, and mechanics, as rationalists, including Louis Pasteur, have maintained?   Empiricists accept the existence of viruses and bacteria as part of nature and illness as part of the life process. They consider fevers, diarrhea, and runny noses good, not bad, and do not suppress them with chemically based drugs that might interfere with the body�s natural ability to harness the immune system to participate in the healing process. They stress that each individual is unique and that individualized therapeutic techniques can stimulate the body to restore health. Empiricists dislike the one-size-fits-all mass vaccination approach.